Corrigendum to: Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma (Cancer Investigation, (2016), 34, 1, (39-44), 10.3109/07357907.2015.1088948);Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma

Cancer Investigation

Volumn 34, Issue 1, 2016, Pages 39-44

  Labussière, Marianne ^a,b,c   Cheneau, Caroline ^a,b,c   Prahst, Claudia ^d,e   Gállego Pérez Larraya, Jaime ^f   Farina, Patrizia ^f   Lombardi, Giuseppe ^f   Mokhtari, Karima ^a,b,c,d,f   Rahimian, Amithys ^d   Delattre, Jean Yves ^a,b,c,d,f   Eichmann, Anne ^b,e   Sanson, Marc ^a,b,c,d,f  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c CNRS   (France)

^d Onconeurotek   (France)

^e l'alimentation et l'Environnement   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Angf; bevacizumab; Glioblastoma; plasma biomarkers

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; PLACENTAL GROWTH FACTOR; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MEMBRANE PROTEIN; PIGF PROTEIN, HUMAN;

ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; DRUG RESISTANCE; FEMALE; MALE; MORTALITY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-2; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; BIOMARKERS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MEMBRANE PROTEINS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84956785905     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357907.2016.1275814     Document Type: Erratum

References (22)

1. Ferrara N., Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005; 438 (7070): 967-974.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285 (21): 1182-1186.
3. Salmaggi A., Eoli M., Frigerio S., Silvani A., Gelati M., Corsini E, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neuro Oncol. 2003; 62 (3): 297-303.
4. Zhou YH., Tan F., Hess KR., Yung WK. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res. 2003; 9 (9): 3369-3375.
5. Schmidt NO., Westphal M., Hagel C., Ergun S., Stavrou D., Rosen EM, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer. 1999; 84 (1): 10-18.
6. Vredenburgh JJ., Desjardins A., Herndon JE, 2nd., Dowell JM., Reardon DA., Quinn JA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13 (4): 1253-1259.
7. Vredenburgh JJ., Desjardins A., Herndon JE, 2nd., Marcello J., Reardon DA., Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25 (30): 4722-4729.
8. Friedman HS., Prados MD., Wen PY., Mikkelsen T., Schiff D., Abrey LE., Yung WK, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27 (28): 4733-4740.
9. Chinot OL., Wick W., Mason W., Henriksson R., Saran F., Nishikawa R., Carpentier AF, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370 (8): 709-722.
10. Gilbert MR., Dignam JJ., Armstrong TS., Wefel JS., Blumenthal DT., Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370 (8): 699-708.
11. Batchelor TT., Reardon DA., de Groot JF., Wick W., Weller M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res. 2014; 20 (22): 5612-5619.
12. Tabouret E., Boudouresque F., Barrie M., Matta M., Boucard C., Loundou A, et al. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol. 2014; 16 (3): 392-399.
13. Hamza MA., Mandel JJ., Conrad CA., Gilbert MR., Yung WK., Puduvalli VK, et al. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neuro Oncol. 2014; 119 (1): 135-140.
14. Bertolini F., Marighetti P., Shaked Y. Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy. Biochim et Biophysica Acta. 2010; 1806 (2): 131-137.
15. Jubb AM., Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010; 11 (12): 1172-1183.
16. Kopetz S., Abbruzzese JL. Hidden biases in an observational study of bevacizumab beyond progression. J Clin Oncol. 2009; 27 (10): 1732-1733; author reply 1733.
17. Willett CG., Duda DG., di Tomaso E., Boucher Y., Ancukiewicz M., Sahani DV, et al. Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study. J Clin Oncol. 2009.
18. Batchelor TT., Duda DG., di Tomaso E., Ancukiewicz M., Plotkin SR., Gerstner E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010; 28 (17): 2817-2823.
19. Chae SS., Kamoun WS., Farrar CT., Kirkpatrick ND., Niemeyer E., de Graaf AM, et al. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res. 2010; 16 (14): 3618-3627.
20. Rigamonti N., Kadioglu E., Keklikoglou I., Wyser Rmili C., Leow CC., De Palma M. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep. 2014; 8 (3): 696-706.
21. Daly C., Eichten A., Castanaro C., Pasnikowski E., Adler A., Lalani AS., Papadopoulos N., et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013; 73 (1): 108-118.
22. Goede V., Coutelle O., Neuneier J., Reinacher-Schick A., Schnell R., Koslowsky TC, et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer. 2010; 103 (9): 1407-1414.